IP Library Granted Patent US 7,850,727
Granted Patent B2
US 7,850,727 · App. 11/273,916 · Granted Dec 14, 2010

Expandable medical device for delivery of beneficial agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,850,727
App. No.
11/273,916
Granted
Dec 14, 2010
Kind
B2
Abstract

An expandable medical device has a plurality of elongated struts joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. At least one of the plurality of struts includes at least one opening extending at least partially through a thickness of the strut. A beneficial agent is loaded into the opening within the strut in layers to achieve desired temporal release kinetics of the agent. Alternatively, the beneficial agent is loaded in a shape which is configured to achieve the desired agent delivery profile. A wide variety of delivery profiles can be achieved including zero order, pulsatile, increasing, decreasing, sinusoidal, and other delivery profiles.

Claims (43)

1. An expandable medical device comprising:

a plurality of struts interconnected to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter; and

a beneficial agent and carrier affixed to the plurality of struts and configured and arranged to control the release kinetics of the beneficial agent to surrounding tissue, wherein the release kinetics include an increasing agent release profile.

2. The device of claim 1 , wherein the beneficial agent is paclitaxel.

3. The device of claim 2 , wherein the carrier includes a barrier layer.

4. The device of claim 2 , wherein the carrier is biodegradable.

5. The device of claim 2 , wherein the paclitaxel and carrier are configured and arranged so that the paclitaxel is 100% discharged from the device.

6. The device of claim 1 , wherein the beneficial agent is an anti-restenotic agent.

7. The device of claim 1 , wherein the beneficial agent is an antithrombin.

8. The device of claim 1 , wherein the beneficial agent is an anti-inflammatory.

9. The device of claim 1 , wherein the carrier includes a barrier layer.

10. The device of claim 9 , wherein the increasing agent release profile when plotted as cumulative agent released versus time provides a curved line with die rate of release of agent increasing over time.

11. The device of claim 1 , wherein the carrier is biodegradable.

12. The device of claim 1 , wherein the beneficial agent and carrier are configured and arranged so that the beneficial agent is 100% discharged from the device.

13. The device of claim 1 , wherein the release kinetics of the beneficial agent to surrounding tissue includes an increasing mural agent release profile.

14. An expandable medical device comprising:

a plurality of struts interconnected to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter;

a beneficial agent and biodegradable carrier affixed to the plurality of struts and configured and arranged to control the temporal release kinetics of the beneficial agent to surrounding tissue, wherein said release kinetics include on increasing agent release profile and 100% discharge of the beneficial agent from the device.

15. The device of claim 14 , wherein the beneficial agent is paclitaxel.

16. The device of claim 14 , wherein the beneficial agent is an anti-restenotic agent.

17. The device of claim 14 , wherein the beneficial agent is an antithrombin.

18. The device of claim 14 , wherein the beneficial agent is an anti-inflammatory.

19. The device of claim 14 , wherein the increasing agent release profile when plotted as cumulative agent released versus time provides a curved line with the rate of release of agent increasing over time.

20. The device of claim 14 , wherein the release kinetics of the beneficial agent to surrounding tissue includes an increasing mural agent release profile.

21. A method of forming an expandable medical device comprising:

providing an expandable medical device with a plurality of struts interconnected to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter;

applying a solution of beneficial agent, biodegradable carrier layer, and solvent to the device and evaporating the solvent to form a solid beneficial agent and carrier layer; and

wherein the beneficial agent and carrier layer are configured and arranged to release the beneficial agent with an increasing agent release profile and 100% discharge of the beneficial agent from the device.

22. The device of claim 21 , wherein the beneficial agent is paclitaxel.

23. The device of claim 21 , wherein the beneficial agent is an anti-restenotic agent.

24. The device of claim 21 , wherein the beneficial agent is an antithrombin.

25. The device of claim 21 , wherein the beneficial agent is an anti-inflammatory.

26. The device of claim 21 , wherein the increasing agent release profile when plotted as cumulative agent released versus time provides a curved line with the rate of release of agent increasing over time.

27. The method of claim 21 , wherein forming a layer with an increasing agent release profile comprises forming a layer with art increasing mural agent release profile.

28. An expandable medical device comprising:

a plurality of struts interconnected to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter;

a beneficial agent and carrier affixed to the plurality of struts and configured and arranged to control the temporal release kinetics of the beneficial agent to surrounding tissue, wherein release kinetics include a two part release profile with both an increasing agent release profile and a decreasing agent release profile.

29. The device of claim 28 , wherein the beneficial agent is paclitaxel.

30. The device of claim 28 , wherein the beneficial agent is an anti-restenotic agent.

31. The device of claim 28 , wherein the beneficial agent is an antithrombin.

32. The device of claim 28 , wherein The beneficial agent is an anti-inflammatory.

33. The device of claim 28 , wherein the two part release profile when plotted as cumulative agent released versus time provides an S-shaped line with the rate of release of agent both increasing and decreasing over time.

34. The device of claim 28 , wherein the release kinetics of the beneficial agent to surrounding tissue includes an increasing mural agent release profile and a decreasing mural agent release profile.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2009
From: CONOR MEDSYSTEMS, INC.
To: INNOVATIONAL HOLDINGS LLC
Reel/Frame 023538/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2007
From: CONOR MEDSYSTEMS, INC.
To: INNOVATIONAL HOLDINGS LLC
Reel/Frame 019955/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2006
From: SHANLEY, JOHN F.
To: CONOR MEDSYSTEMS, INC.
Reel/Frame 017968/0944 →